Broad Spectrum Distillate
CBD Isolate
CBG Isolate
Water Soluble CBD Isolate
Water Soluble CBD Broad Spectrum
Back to news
10. February 2021
Corporate News Medical News

PAOG Targets $3.8 Billion CBD Nutraceuticals Market

PAO Group, Inc. (USOTC: PAOG) has revealed plans to expand its nutraceutical product reach. The company plans to produce nutraceuticals for additional applications beyond the current focus on care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD).

Last year, PAOG acquired RespRx from Kali-Extracts. RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method – U.S. Patent No. 9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.”

In addition to PAOG’s ongoing efforts to develop a pharmaceutical treatment for COPD, the company has announced engaging with the Puerto Rico Consortium for Clinical Investigation (PRCCI) to assist in the development of a proprietary Cannabidiol (CBD) extract that can be turned into a nutraceutical product to provide care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD).

CBD nutraceutical market

PAOG recently revealed its strategy for targeting a broader nutraceutical development initiative with plans to produce nutraceuticals for additional applications. The CBD nutraceutical market was valued at $3.8 billion in 2018 forecasted to grow at CAGR of over 18%.

PAOG plans to establish a revenue stream this year from its nutraceuticals’ initiative adding to its recently confirmed a $300,000 sales agreement executed by the company’s cannabis cultivation subsidiary. The manufacturer anticipates approximately $50,000 in revenue per quarter for six quarters starting with an estimated $50,000 in revenue expected to be reported for Q4 2020.

Last summer, PAOG acquired a cannabis cultivation business from Puration, Inc. (USOTC: PURA). The acquisition was made in conjunction with the company’s overall strategy to refresh and renew its overall cannabis healthcare industry strategy.

PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, as a copacker and North American Cannabis Holdings, as a distributor.

Source | PAOG